Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Natera Inc. Common Stock — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.8 (market cap $44.60B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and JPMorgan Nasdaq Equity Premium Income ETF is more actively traded (3,957,816 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 67 Days and Natera Inc. Common Stock for 0 Days on average.
| JEPQ | NTRA | |
|---|---|---|
Market Cap | $44.60B | $57.03B |
Volume | 3,957,816 | 1,131,157 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $425.64 |
52-Week Low | $53.77 | $179.42 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $60.92, showing minimal daily movement with a neutral technical signal. The ETF maintains a covered-call strategy focused on Nasdaq exposure, generating monthly income through dividends. Recent distributions have shown variability, with payouts ranging from $0.57 to $0.70 per share. Moving averages indicate bullish momentum while oscillators remain neutral, suggesting balanced near-term positioning.
The ETF offers high-yield income potential with an estimated 11% annualized yield, though price appreciation may be limited by the covered-call strategy. Key risks include market volatility dependence and potential tax implications from return of capital. Institutional interest remains strong, with recent acquisitions signaling confidence in the income strategy.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
